Chong Kun Dang Pharmaceutical Corp.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)
- Conditions
- Hypertension
- Interventions
- Drug: CKD-330 8/5mg
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT02186496
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Chungcheongbuk-do, Korea, Republic of
Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 41
- Registration Number
- NCT02156544
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of
CKD-337 Drug Interaction Study
- Conditions
- Dyslipidemia (Fredrickson Type Ⅱb)Dyslipidemia (Fredrickson Type Ⅱa)
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT02066207
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
CKD-330 Drug-Drug Interaction Study (Candesartan)
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT02064621
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
CKD-330 Drug-Drug Interaction Study (Amlodipine)
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT02064556
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
- Conditions
- HyperlipidemiaHypertension
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 64
- Registration Number
- NCT02047175
- Locations
- 🇰🇷
The catholic university of Korea, seoul ST.Mary's hospital, Seoul, Gangnam-gu, Korea, Republic of
Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT02007941
- Locations
- 🇰🇷
The Inje University Busan Paik Hospital, Busan, Korea, Republic of
Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 60
- Registration Number
- NCT02005757
- Locations
- 🇰🇷
Eulji University Hospital, Daejeon, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Kangwon National University Hospital, Kangwon, Korea, Republic of
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 26
- Registration Number
- NCT02005744
- Locations
- 🇰🇷
Yonsei University Severance Hospital, Soeul, Korea, Republic of
Drug-drug Interaction Study(Lobeglitazone, Warfarin)
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT02002611
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of